Want to see HK:1789 full AI Analyst Report?
Top Page
AK Medical Holdings Ltd.
(1789)
Select Model
Select Model
Rating:72Outperform
Price Target:
HK$5.00
▼(-15.40% Downside)
Action:Upgraded
Date:08/06/26
The score is driven primarily by solid financial fundamentals—strong margins and an exceptionally low-leverage balance sheet—tempered by uneven cash-flow conversion. Technicals are neutral-to-slightly positive but constrained by weaker positioning versus longer-term moving averages, while valuation is fair with a mid-teens P/E and a modest dividend yield.
Positive Factors
Strong Profitability
High gross, operating, and net margins demonstrate strong economics in the orthopedic device business and indicate effective cost discipline. These margins provide internal funding capacity for product development and commercial investment, while creating resilience if demand or pricing becomes less favorable.
Negative Factors
Cash-Flow Volatility
The sharp deterioration in 2023 shows that reported profitability does not always translate smoothly into cash generation. Such volatility can make internal funding less predictable and may complicate investment planning, even though cash flow recovered to positive levels by 2025.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
High gross, operating, and net margins demonstrate strong economics in the orthopedic device business and indicate effective cost discipline. These margins provide internal funding capacity for product development and commercial investment, while creating resilience if demand or pricing becomes less favorable.
Read all positive factors
AK Medical Holdings Ltd. (1789) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$5.05B
Dividend Yield2.59%
Average Volume (3M)2.19M
Price to Earnings (P/E)11.4
Beta (1Y)0.92
Revenue Growth16.15%
EPS Growth31.89%
CountryHK
Employees1,004
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.34
Shares Outstanding1,109,980,300
10 Day Avg. Volume2,422,809
30 Day Avg. Volume2,194,868
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)1.97
Price to Sales (P/S)3.87
P/FCF Ratio18.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$17.21Price Target Upside191.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.37
Revenue Forecast (FY)HK$1.66B
AK Medical Holdings Ltd. Business Overview & Revenue Model
Company Description
AK Medical Holdings Limited, an investment holding enterprise, specializes in the research, development, production, and worldwide commercialization of orthopedic joint implants and related medical devices under the AK Medical brand. Its comprehen...
How the Company Makes Money
AK Medical primarily makes money by selling orthopedic medical devices used in joint replacement and related orthopedic surgeries. Its core revenue stream is the sale of orthopedic implants (e.g., hip and knee replacement components) to hospitals ...
AK Medical Holdings Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
88
Very Positive
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.55B | 1.48B | 1.35B | 1.09B | 1.05B | 761.44M |
| Gross Profit | 974.50M | 897.39M | 808.19M | 674.49M | 636.43M | 499.19M |
| EBITDA | 538.15M | 480.76M | 397.12M | 323.34M | 322.87M | 184.33M |
| Net Income | 375.20M | 339.09M | 273.93M | 182.10M | 204.77M | 92.62M |
Balance Sheet | ||||||
| Total Assets | 3.54B | 3.66B | 3.34B | 3.00B | 2.77B | 2.61B |
| Cash, Cash Equivalents and Short-Term Investments | 1.19B | 1.47B | 1.05B | 726.67M | 1.04B | 841.13M |
| Total Debt | 12.93M | 144.79M | 99.39M | 84.20M | 38.78M | 41.56M |
| Total Liabilities | 787.87M | 750.15M | 697.21M | 611.12M | 530.73M | 573.73M |
| Stockholders Equity | 2.75B | 2.91B | 2.64B | 2.39B | 2.24B | 2.03B |
Cash Flow | ||||||
| Free Cash Flow | 328.02M | 316.09M | 289.11M | -162.14M | 121.20M | 100.39M |
| Operating Cash Flow | 407.24M | 419.03M | 451.07M | 33.94M | 242.92M | 176.62M |
| Investing Cash Flow | 789.30M | -316.18M | -393.35M | -318.15M | -82.29M | -297.10M |
| Financing Cash Flow | -461.45M | -83.26M | -39.43M | -14.02M | -36.80M | -100.70M |
AK Medical Holdings Ltd. Technical Analysis
Neutral
5.91
Price Trends
4.88
Negative
5.20
Negative
5.61
Negative
Market Momentum
-0.11
Negative
44.76
Neutral
78.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1789, the sentiment is Neutral. The current price of 5.91 is above the 20-day moving average (MA) of 4.56, above the 50-day MA of 4.88, and above the 200-day MA of 5.61, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 44.76 is Neutral, neither overbought nor oversold. The STOCH value of 78.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1789.
AK Medical Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$5.05B | 11.38 | 13.24% | 2.59% | 16.15% | 31.89% | |
59 Neutral | HK$6.35B | 98.22 | 1.71% | ― | 0.75% | -20.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.63B | -0.86 | -6.69% | ― | ― | ― | |
46 Neutral | HK$11.65B | 31.23 | 6.07% | 0.06% | -3.62% | ― | |
44 Neutral | HK$432.19M | -0.78 | -28.24% | ― | -38.15% | 25.70% | |
42 Neutral | HK$21.97B | -74.88 | -52.78% | ― | 114.97% | 63.21% |
* Healthcare Sector Average
HK:1789
AK Medical Holdings Ltd.
4.56
-1.34
-22.75%
HK:0853
MicroPort Scientific
6.08
-5.92
-49.33%
HK:1302
LifeTech Scientific Corporation
1.47
-0.58
-28.29%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.28
-4.67
-78.49%
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
21.18
-5.94
-21.90%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
0.98
-1.77
-64.36%
AK Medical Holdings Ltd. Corporate Events
AK Medical Boosts Dividend Payout Ratios Through 2028
Sep 9, 2026
AK Medical Holdings Limited has introduced a new shareholder dividend distribution and return plan that materially raises its payout ratios over the next three financial years. For the year ending 31 December 2026, the board has set a minimum annu...
AK Medical Delivers Double-Digit Profit Growth on Higher-Margin Overseas and Digital Sales
Aug 26, 2026
AK Medical reported unaudited interim results for the six months ended 30 June 2026 showing solid operational and financial momentum. Revenue rose 10.2% year-on-year to RMB764.7 million, while gross profit climbed 18.8% to RMB487.4 million, reflec...
AK Medical Sets August Board Meeting to Review Interim Results and Dividend
Aug 14, 2026
AK Medical Holdings Limited has scheduled a board meeting for 26 August 2026 at its Global Operation Center in Beijing to review and approve the Group’s interim results for the six months ended 30 June 2026. The board will also consider the ...
AK Medical reshapes company secretarial roles under Hong Kong Listing Rules waiver
Aug 7, 2026
AK Medical Holdings Ltd. has announced that company secretary and authorised representative Ms. Ma Rongkun will resign effective 7 August 2026, citing personal career plans and confirming no disagreement with the board or matters requiring shareho...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.